Evaluation of a Desipramine Ceiling in Cocaine Abuse - 1

This study has been completed.

First Received: September 20, 1999 Last Updated: August 16, 2005 History of Changes

Sponsor:	National Institute on Drug Abuse (NIDA)
Collaborator:	Friends Research Institute, Inc.
Information provided by:	National Institute on Drug Abuse (NIDA)
ClinicalTrials.gov Identifier:	NCT00000245

Purpose

The purpose of this study is to confirm whether a blood level ""ceiling"" exists on desipramine effect in cocaine abuse.

Condition	Intervention	Phase
Cocaine-Related Disorders Substance-Related Disorders	Drug: Desipramine	Phase II

Study Type:	Interventional
Study Design:	Treatment
Official Title:	Evaluation of a Desipramine Ceiling in Cocaine Abuse

Resource links provided by NLM:

Drug Information available for: Desipramine Desipramine hydrochloride

U.S. FDA Resources

Further study details as provided by National Institute on Drug Abuse (NIDA):

Primary Outcome Measures:

Craving
Retention
Cocaine use
Depression
Anxiety
Mood indicators

Estimated Enrollment:	0
Study Start Date:	May 1994
Estimated Study Completion Date:	December 2001

Eligibility

Ages Eligible for Study:	18 Years to 65 Years
Genders Eligible for Study:	Both
Accepts Healthy Volunteers:	No

Criteria

Please contact site for information.

Contacts and Locations

Please refer to this study by its ClinicalTrials.gov identifier: NCT00000245

Locations

United States, California
Friends Research Institute
Los Angeles, California, United States, 90025

Sponsors and Collaborators

National Institute on Drug Abuse (NIDA)

Friends Research Institute, Inc.

Investigators

Principal Investigator:

Frank Gawin, M.D.

Friends Research Institute, Inc.

More Information

No publications provided

Study ID Numbers:	NIDA-08082-1, R01-08082-1
Study First Received:	September 20, 1999
Last Updated:	August 16, 2005
ClinicalTrials.gov Identifier:	NCT00000245 History of Changes
Health Authority:	United States: Federal Government

Additional relevant MeSH terms:

Cocaine-Related Disorders
Neurotransmitter Uptake Inhibitors
Neurotransmitter Agents
Disease
Adrenergic Agents
Molecular Mechanisms of Pharmacological Action
Adrenergic Uptake Inhibitors
Physiological Effects of Drugs
Psychotropic Drugs
Disorders of Environmental Origin

Enzyme Inhibitors
Desipramine
Pharmacologic Actions
Antidepressive Agents, Tricyclic
Pathologic Processes
Mental Disorders
Therapeutic Uses
Substance-Related Disorders
Central Nervous System Agents
Antidepressive Agents

ClinicalTrials.gov processed this record on November 09, 2009